Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial
about
Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Efficacy of Rituximab in Refra ...... An Open-Label, Phase II Trial
@ast
Efficacy of Rituximab in Refra ...... An Open-Label, Phase II Trial
@en
type
label
Efficacy of Rituximab in Refra ...... An Open-Label, Phase II Trial
@ast
Efficacy of Rituximab in Refra ...... An Open-Label, Phase II Trial
@en
prefLabel
Efficacy of Rituximab in Refra ...... An Open-Label, Phase II Trial
@ast
Efficacy of Rituximab in Refra ...... An Open-Label, Phase II Trial
@en
P2093
P2860
P50
P1433
P1476
Efficacy of Rituximab in Refra ...... An Open-Label, Phase II Trial
@en
P2093
Adrian Hij
Aude Rigolet
Fabienne Jouen
Herve Devilliers
Isabelle Marie
Kuberaka Mariampillai
Laurent Drouot
Lucile Musset
Marguerite Guiguet
Olivier Benveniste
P2860
P304
P356
10.1371/JOURNAL.PONE.0133702
P407
P577
2015-11-05T00:00:00Z